Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+-binding protein S100A6 in papillary thyroid carcinoma

Thyroid

Volumn 20, Issue 10, 2010, Pages 1067-1076

  Sofiadis, Anastasios ^a   Dinets, Andrii ^a,b   Orre, Lukas M ^c   Branca, Rui M ^c   Juhlin, Carl Christofer ^a,c   Foukakis, Theodoros ^a,c   Wallin, Göran ^a   Höög, Anders ^a,c   Hulchiy, Mykola ^b   Zedenius, Jan ^a   Larsson, Catharina ^a   Lehtiö, Janne ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Kyiv City Teaching Endocrinological Center   (Ukraine)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCIUM BINDING PROTEIN; CALCYCLIN; PROTEIN S 100; PROTEIN S 100A6; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CELL CYCLE PROTEINS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; S100 PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION;

EID: 77957905078     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0400     Document Type: Article

References (37)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) 2004 Tumours of the thyroid and parathyroid. In: WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon, France, pp 49-133.
2. Lundgren CI, Zedenius J, Skoog L 2008 Fine-needle aspiration biopsy of benign thyroid nodules: an evidence-based review. World J Surg 32:1247-1252.
3. Gharib H, Goellner JR 1993 Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 118:282-289.
4. Hegedus L 2004 Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771.
5. Krause K, Jessnitzer B, Fuhrer D 2009 Proteomics in thyroid tumor research. J Clin Endocrinol Metab 94:2717-2724.
6. Moore BW 1965 A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739-744.
7. Cross SS, Hamdy FC, Deloulme JC, Rehman I 2005 Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46:256-269.
8. Schafer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW 1995 Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25:638-643.
9. Salama I, Malone PS, Mihaimeed F, Jones JL 2008 A review of the S100 proteins in cancer. Eur J Surg Oncol 34:357-364.
10. Kuznicki J, Filipek A 1987 Purification and properties of a novel Ca2+-binding protein (10.5 kDa) from Ehrlich-ascitestumour cells. Biochem J 247:663-667.
11. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtio J 2009 Tumor expression of S100A6 correlates with survival of patients with stage I non-smallcell lung cancer. Lung Cancer 63:410-417.
12. Kim J, Kim J, Yoon S, Joo J, Lee Y, Lee K, Chung J, Choe I 2002 S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol Res 23:274.
13. Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, Kameyama M, Miyoshi J, Akedo H, Nakamura H 2000 Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 6:172-177.
14. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O 1997 Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74:464-469.
15. Stulik J, Osterreicher J, Koupilova K, Knizek J, Bures J, Jandik P, Langr F, Dedic K, Schafer BW, Heizmann CW 2000 Differential expression of the Ca2+ binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 36:1050-1059.
16. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245-262.
17. Forsberg L, Larsson C, Sofiadis A, Lewensohn R, Hoog A, Lehtio J 2006 Pre-fractionation of archival frozen tumours for proteomics applications. J Biotechnol 126:582-586.
18. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
19. Vimalachandran D, Greenhalf W, Thompson C, Luttges J, Prime W, Campbell F, Dodson A, Watson R, Crnogorac-Jurcevic T, Lemoine N, Neoptolemos J, Costello E 2005 High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 65:3218-3225.
20. Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, Rudduck C, Lui WO, Hoog A, Larsson C 2007 Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid 17:289-301.
21. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
22. Orre LM, Pernemalm M, Lengqvist J, Lewensohn R, Lehtio J 2007 Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol Cell Proteomics 6:2122-2131.
23. Huang S, Elliott RC, Liu PS, Koduri RK, Weickmann JL, Lee JH, Blair LC, Ghosh-Dastidar P, Bradshaw RA, Bryan KM, et al. 1987 Specificity of cotranslational amino-terminal processing of proteins in yeast. Biochemistry 26:8242-8246.
24. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954.
25. Torres-Cabala C, Panizo-Santos A, Krutzsch HC, Barazi H, Namba M, Sakaguchi M, Roberts DD, Merino MJ 2004 Differential expression of S100C in thyroid lesions. Int J Surg Pathol 12:107-115.
26. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A 2004 S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 67:397-402.
27. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y 2005 S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 93:1277-1284.
28. Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Res 29:4157-4161.
29. Komatsu K, Murata K, Kameyama M, Ayaki M, Mukai M, Ishiguro S, Miyoshi J, Tatsuta M, Inoue M, Nakamura H 2002 Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology 63:192-200.
30. Yang YQ, Zhang LJ, Dong H, Jiang CL, Zhu ZG, Wu JX, Wu YL, Han JS, Xiao HS, Gao HJ, Zhang QH 2007 Upregulated expression of S100A6 in human gastric cancer. J Dig Dis 8:186-193.
31. Fullen DR, Garrisi AJ, Sanders D, Thomas D 2008 Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays. J Cutan Pathol 35 Suppl 2:28-34.
32. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A 2005 Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology 46:569-575.
33. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR 2006 Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45:613-626.
34. Matsuzawa SI, Reed JC 2001 Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7:915-926.
35. Fernandez-Fernandez MR, Rutherford TJ, Fersht AR 2008 Members of the S100 family bind p53 in two distinct ways. Protein Sci. 17:1663-1670.
36. Slomnicki LP, Nawrot B, Lesniak W 2009 S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol 41:784-790.
37. Joo JH, Yoon SY, Kim JH, Paik SG, Min SR, Lim JS, Choe IS, Choi I, Kim JW 2008 S100A6 (calcyclin) enhances the sensitivity to apoptosis via the upregulation of caspase-3 activity in Hep3B cells. J Cell Biochem 103:1183-1197.